Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Management
Genes · 2025
DOI: 10.3390/genes16040402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Genes, 2025. Verfasst von Giuseppe Fabio Parisi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, 95121 Catania, Italy. Hauptthemen laut MEDLINE: Cystic Fibrosis, Precision Medicine, Genetic Therapy. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cystic fibrosis (CF), a genetic disorder characterized by mutations in the CFTR gene, has seen significant advances in treatment through cutting-edge approaches such as gene therapy and personalized medicine. This review examines the current and emerging strategies shaping CF care, focusing on novel therapies that target the root cause of CF and optimize patient outcomes. CFTR modulators have transformed cystic fibrosis management by enhancing protein function for specific mutations, leading to improved lung function and quality of life. Concurrently, gene therapy offers transformative potential by aiming to correct CFTR mutations using tools like CRISPR/Cas9 or prime editing, though challenges remain in delivery and long-term efficacy. The integration of precision medicine, facilitated by genomic and computational technologies, allows for personalized treatment plans that account for genetic variability and disease severity. Complementing these approaches, holistic management emphasizes the importance of psychological support and nutritional optimization, acknowledging CF’s multi-system impact. Future directions include exploring anti-inflammatory agents and microbiome modulation to further mitigate disease morbidity. However, global disparities in treatment access continue to challenge equitable healthcare delivery, underscoring the need for policy reform and international cooperation. By synthesizing these developments, this review highlights the transformative potential of modern CF treatments, advocating for continued innovation and global healthcare equity, with the ultimate goal of dramatically improving life expectancy and quality of life for individuals with CF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Respiratory Unit, Department of Clinical and Experimental Medicine, San Marco Hospital, University of Catania, 95121 Catania, Italy.
- Cystic Fibrosis Regional Reference Centre, Department of Paediatric Medicine, Meyer Children's Hospital IRCCS, Viale Gaetano Pieraccini 24, 50139 Florence, Italy.
- Pediatric Unit, Department of Human and Pediatric Pathology "Gaetano Barresi", Azienda Ospedaliera Universitaria Policlinico "G. Martino", University of Messina, Via Consolare Valeria, 1, 98124 Messina, Italy.
ORCID-Profile: Giuseppe Fabio Parisi, Vito Terlizzi, Sara Manti, Giulia Pecora, Santiago Presti, Salvatore Leonardi
Zitieren
APA
Parisi, G. F., Terlizzi, V., Manti, S., Papale, M., Pecora, G., Presti, S., Tosto, M., & Leonardi, S. (2025). Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Management. Genes. https://doi.org/10.3390/genes16040402
Vancouver
Parisi GF, Terlizzi V, Manti S, Papale M, Pecora G, Presti S, et al. Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Management. Genes. 2025. doi:10.3390/genes16040402
BibTeX
@article{Parisi2025,
author = {Parisi, Giuseppe Fabio and Terlizzi, Vito and Manti, Sara and Papale, Maria and Pecora, Giulia and Presti, Santiago and Tosto, Monica and Leonardi, Salvatore},
title = {Cutting-Edge Advances in Cystic Fibrosis: From Gene Therapy to Personalized Medicine and Holistic Management},
journal = {Genes},
year = {2025},
doi = {10.3390/genes16040402}
}
EUVIMED